Toll Free: 1-888-928-9744

Melinta Therapeutics, Inc - Product Pipeline Review - 2014

Published: Dec, 2014 | Pages: 49 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Melinta Therapeutics, Inc - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Melinta Therapeutics, Inc - Product Pipeline Review - 2014', provides an overview of the Melinta Therapeutics, Inc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Melinta Therapeutics, Inc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Melinta Therapeutics, Inc including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Melinta Therapeutics, Inc's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Melinta Therapeutics, Inc's pipeline products

Reasons to buy

- Evaluate Melinta Therapeutics, Inc's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Melinta Therapeutics, Inc in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Melinta Therapeutics, Inc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Melinta Therapeutics, Inc and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Melinta Therapeutics, Inc
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Melinta Therapeutics, Inc and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Melinta Therapeutics, Inc Snapshot 5
Melinta Therapeutics, Inc Overview 5
Key Information 5
Key Facts 5
Melinta Therapeutics, Inc - Research and Development Overview 6
Key Therapeutic Areas 6
Melinta Therapeutics, Inc - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Melinta Therapeutics, Inc - Pipeline Products Glance 12
Melinta Therapeutics, Inc - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Melinta Therapeutics, Inc - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Melinta Therapeutics, Inc - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Melinta Therapeutics, Inc - Drug Profiles 16
delafloxacin 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
radezolid 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
RX-02 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
RX-04 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
RX-05 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
RXP-792 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
RXP-873 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
RXP-763 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
RXP-766 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RXP-770 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
RXP-793 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
RXP-808 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Melinta Therapeutics, Inc - Pipeline Analysis 34
Melinta Therapeutics, Inc - Pipeline Products by Target 34
Melinta Therapeutics, Inc - Pipeline Products by Route of Administration 35
Melinta Therapeutics, Inc - Pipeline Products by Molecule Type 36
Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action 37
Melinta Therapeutics, Inc - Recent Pipeline Updates 38
Melinta Therapeutics, Inc - Dormant Projects 45
Melinta Therapeutics, Inc - Company Statement 46
Melinta Therapeutics, Inc - Locations And Subsidiaries 47
Head Office 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Melinta Therapeutics, Inc, Key Information 5
Melinta Therapeutics, Inc, Key Facts 5
Melinta Therapeutics, Inc - Pipeline by Indication, 2014 8
Melinta Therapeutics, Inc - Pipeline by Stage of Development, 2014 10
Melinta Therapeutics, Inc - Monotherapy Products in Pipeline, 2014 11
Melinta Therapeutics, Inc - Phase III, 2014 12
Melinta Therapeutics, Inc - Phase II, 2014 13
Melinta Therapeutics, Inc - Preclinical, 2014 14
Melinta Therapeutics, Inc - Discovery, 2014 15
Melinta Therapeutics, Inc - Pipeline by Target, 2014 34
Melinta Therapeutics, Inc - Pipeline by Route of Administration, 2014 35
Melinta Therapeutics, Inc - Pipeline by Molecule Type, 2014 36
Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action, 2014 37
Melinta Therapeutics, Inc - Recent Pipeline Updates, 2014 38
Melinta Therapeutics, Inc - Dormant Developmental Projects,2014 45 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify